Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen Inc. | -0.30% | 357.04 | 1.2% | $818.74m | |
| AMGN | Amgen Inc. | -0.98% | 189.88 | 1.2% | $543.49m | |
| CELG | Celgene Corporation | -0.31% | 85.08 | 1.2% | $517.86m | |
| GILD | Gilead Sciences, Inc. | -0.03% | 77.03 | 0.9% | $473.33m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.14% | 178.06 | 1.9% | $311.94m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.42% | 366.19 | 2.6% | $283.24m | |
| ILMN | Illumina, Inc. | 0.44% | 310.46 | 3.5% | $265.60m | |
| SRPT | Sarepta Therapeutics, Inc. | -0.39% | 135.01 | 16.6% | $231.23m | |
| BLUE | Bluebird Bio, Inc. | 1.06% | 180.85 | 15.7% | $204.08m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.05% | 135.16 | 2.0% | $176.64m | |
| NKTR | Nektar Therapeutics | -1.30% | 48.44 | 5.6% | $171.79m | |
| EXAS | Exact Sciences Corporation | 0.58% | 68.00 | 25.4% | $159.68m | |
| EXEL | Exelixis, Inc. | -0.47% | 21.24 | 6.4% | $135.76m | |
| BMRN | BioMarin Pharmaceutical Inc. | -0.90% | 101.94 | 4.4% | $124.01m | |
| A | Agilent Technologies, Inc. | 0.14% | 64.24 | 1.5% | $122.79m |
Company Profile
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.